Importer of Controlled Substances Application: Royal Emerald Pharmaceuticals, 47176-47177 [2024-11891]
Download as PDF
<![CDATA[
47176
Federal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Notices
chromium-coated steel sheet from Japan
would be likely to lead to continuation
or recurrence of material injury to an
industry in the United States within a
reasonably foreseeable time.
Background
The Commission instituted this
review on June 1, 2023 (88 FR 35920)
and determined on September 5, 2023
that it would conduct a full review (88
FR 64464, September 19, 2023). Notice
of the scheduling of the Commission’s
review and of a public hearing to be
held in connection therewith was given
by posting copies of the notice in the
Office of the Secretary, U.S.
International Trade Commission,
Washington, DC, and by publishing the
notice in the Federal Register on
October 30, 2023 (88 FR 74209). The
Commission conducted its hearing on
April 9, 2024. All persons who
requested the opportunity were
permitted to participate.
The Commission made this
determination pursuant to section
751(c) of the Act (19 U.S.C. 1675(c)). It
completed and filed its determination in
this review on May 28, 2024. The views
of the Commission are contained in
USITC Publication 5507 (May 2024),
entitled Tin- and Chromium-Coated
Steel Sheet from Japan: Investigation
No. 731–TA–860 (Fourth Review).
Controlled
substance
Drug code
Psilocybin ...............
Levorphanol ............
By order of the Commission.
Issued: May 28, 2024.
Lisa Barton,
Secretary to the Commission.
I
7437
9220
Schedule
I
I
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use or for
sale to its customers. No other activities
for these drug codes are authorized for
this registration.
[FR Doc. 2024–12014 Filed 5–30–24; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Matthew J. Strait,
Deputy Assistant Administrator.
Drug Enforcement Administration
[FR Doc. 2024–11879 Filed 5–30–24; 8:45 am]
[Docket No. DEA–1365]
BILLING CODE P
Bulk Manufacturer of Controlled
Substances Application: ANI
Pharmaceuticals, Inc.
DEPARTMENT OF JUSTICE
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Drug Enforcement Administration
ANI Pharmaceuticals, Inc. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 30, 2024. Such persons
Importer of Controlled Substances
Application: Royal Emerald
Pharmaceuticals
AGENCY:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
may also file a written request for a
hearing on the application on or before
July 30, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on April 9, 2024, ANI
Pharmaceuticals, Inc., 70 Lake Drive,
East Windsor, New Jersey 08520,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
VerDate Sep<11>2014
17:22 May 30, 2024
Jkt 262001
listed below for further drug
information.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 1, 2024. Such persons
may also file a written request for a
hearing on the application on or before
July 1, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2024, Royal
Emerald Pharmaceuticals, 14011 Palm
Drive, Building B, Desert Hot Spring,
California 92240–6845, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
DATES:
[Docket No. DEA–1380]
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Royal Emerald
Pharmaceuticals has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Controlled
substance
Marihuana Extract ..
Marihuana ...............
Tetrahydrocannabinols.
Drug code
7350
7360
7370
Schedule
I
I
I
The company plans to import
Marihuana seeds and immature
Marihuana plants in the form of Active
Pharmaceutical Ingredients (API) and
botanical raw materials for Drug
Enforcement Administration-approved
E:\FR\FM\31MYN1.SGM
31MYN1
47177
Federal Register / Vol. 89, No. 106 / Friday, May 31, 2024 / Notices
legitimate scientific medical research
and/or industrial purposes.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2024–11891 Filed 5–30–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1379]
Importer of Controlled Substances
Application: United States
Pharmacopeial Convention
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
United States Pharmacopeial
Convention has applied to be registered
as an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 1, 2024. Such persons
may also file a written request for a
hearing on the application on or before
July 1, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
SUMMARY:
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on April 5, 2024, United
States Pharmacopeial Convention, 7135
English Muffin Way, Frederick,
Maryland 21704, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
Controlled substance
Drug code
Cathinone ........................................................................................................................................................................
Methcathinone .................................................................................................................................................................
Methaqualone ..................................................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine .............................................................................................................................
3,4-Methylenedioxyamphetamine ....................................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................
Difenoxin ..........................................................................................................................................................................
Heroin ..............................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Phenmetrazine .................................................................................................................................................................
Methylphenidate ..............................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................
Secobarbital .....................................................................................................................................................................
Glutethimide .....................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................
Phenylacetone .................................................................................................................................................................
Alphaprodine ....................................................................................................................................................................
Anileridine ........................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Thebaine ..........................................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
VerDate Sep<11>2014
17:22 May 30, 2024
Jkt 262001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
E:\FR\FM\31MYN1.SGM
31MYN1
1235
1237
2565
7315
7395
7400
7411
9053
9168
9200
9307
9634
1105
1205
1631
1724
2125
2270
2315
2550
7471
8333
8501
9010
9020
9041
9120
9170
9210
9220
9230
9273
9333
9652
9668
9737
9740
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 89, Number 106 (Friday, May 31, 2024)]
[Notices]
[Pages 47176-47177]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11891]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1380]
Importer of Controlled Substances Application: Royal Emerald
Pharmaceuticals
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Royal Emerald Pharmaceuticals has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
July 1, 2024. Such persons may also file a written request for a
hearing on the application on or before July 1, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on April 10, 2024, Royal Emerald Pharmaceuticals, 14011
Palm Drive, Building B, Desert Hot Spring, California 92240-6845,
applied to be registered as an importer of the following basic
class(es) of controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract.................... 7350 I
Marihuana............................ 7360 I
Tetrahydrocannabinols................ 7370 I
------------------------------------------------------------------------
The company plans to import Marihuana seeds and immature Marihuana
plants in the form of Active Pharmaceutical Ingredients (API) and
botanical raw materials for Drug Enforcement Administration-approved
[[Page 47177]]
legitimate scientific medical research and/or industrial purposes.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2024-11891 Filed 5-30-24; 8:45 am]
BILLING CODE P
